Silexion Therapeutics Corp (SLXN) Stock Price & Analysis
Silexion Therapeutics Corp (SLXN) fell 16.52% to USD 4.17 as of June 10, 2026 at 01:05 UTC, according to Nexqual real-time market data.
SLXN last closed at USD 5; the session ranged USD 4.06–5.1 on volume of 74,660 shares. Market capitalization is $1.75M, with a 52-week range of USD 2.31–223.6 (NCM). Source: Nexqual, June 10, 2026 at 01:05 UTC.
Key Statistics (as of June 10, 2026 at 01:05 UTC)
| Price | USD 4.17 |
|---|---|
| Change | ▼ 16.52% (down) |
| Previous Close | USD 5 |
| Open | USD 5.1 |
| Day Range | USD 4.06 – 5.1 |
| 52-Week Range | USD 2.31 – 223.6 |
| Volume | 74,660 shares |
| Market Cap | $1.75M |
| Exchange | NCM |
Technical Analysis (SLXN)
Nexqual's technical model rates SLXN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.21 (neutral) |
| vs SMA50 | Below (USD 7.19) |
| MACD | -0.67 (negative) |
Analyst Ratings (SLXN)
Wall Street analysts rate SLXN "None" based on 2 analysts, with a mean price target of USD 60 (range USD 60–60), per Nexqual as of June 10, 2026 at 01:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 60 |
| High Target | USD 60 |
| Low Target | USD 60 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (SLXN)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -8.5 vs est -12.9 ▲ beat |
| 2025-09-30 | USD -28.8 vs est -34 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Financials & Fundamentals (SLXN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -897.46% |
| Debt / Equity | 683.51 |
| Current Ratio | 1 |
| Total Cash | $2.41M |
| Total Debt | $1.99M |
| Free Cash Flow | $-7.49M |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Financial Health Score (SLXN)
Nexqual rates Silexion Therapeutics Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $2M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$12M |
| Efficiency | Critical — ROE -897%, ROA -123.3% |
Ownership (SLXN)
| Insider Ownership | +40.83% |
|---|---|
| Institutional Ownership | +4.55% |
| Shares Outstanding | 418,995 |
| Float | 414,621 |
| Short % of Float | +4.49% |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Leadership (SLXN)
Silexion Therapeutics Corp is led by Ilan Hadar (age 56), Chairman & CEO, per Nexqual as of June 10, 2026 at 01:05 UTC.
| Chairman & CEO | Ilan Hadar (age 56) |
|---|---|
| EVP of Finance Affairs, CFO & Secretary | Mirit Horenshtein Hadar (age 41) |
| Chief Scientific & Development Officer | Mitchell Shirvan (age 71) |
From Silexion Therapeutics Corp's Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
- The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
- Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
- Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
| TRNR | Interactive Strength Inc. | USD 0.7 | ▼ 6.21% |
| HCWB | HCW Biologics Inc. | USD 1.18 | ▼ 27.61% |
| NVNI | Nvni Group Limited | USD 1 | ▼ 1.96% |
| ONCO | Onconetix, Inc. | USD 0.95 | ▼ 8.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:05 UTC. This page is informational and not investment advice.